IsoRay (ISR) Sees Unusually-High Trading Volume
IsoRay, Inc. (NYSEAMERICAN:ISR) shares saw unusually-strong trading volume on Tuesday . Approximately 1,279,800 shares changed hands during mid-day trading, an increase of 586% from the previous session’s volume of 186,685 shares.The stock last traded at $0.43 and had previously closed at $0.40.
Several equities analysts have issued reports on ISR shares. Maxim Group cut shares of IsoRay from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. Zacks Investment Research cut shares of IsoRay from a “hold” rating to a “sell” rating in a research note on Friday, November 16th. Finally, HC Wainwright set a $1.00 price objective on shares of IsoRay and gave the company a “hold” rating in a research note on Tuesday, November 13th.
IsoRay (NYSEAMERICAN:ISR) last announced its quarterly earnings data on Thursday, November 8th. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $1.73 million.
A hedge fund recently raised its stake in IsoRay stock. Vanguard Group Inc. increased its holdings in IsoRay, Inc. (NYSEAMERICAN:ISR) by 24.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,857,268 shares of the healthcare company’s stock after buying an additional 367,324 shares during the period. Vanguard Group Inc. owned about 2.76% of IsoRay worth $964,000 as of its most recent SEC filing.
About IsoRay (NYSEAMERICAN:ISR)
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Featured Article: QQQ ETF
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.